Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average ...

BOSTON, November 04, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2024, and raised its full-year ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report).

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the ...

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), ...